Real-Life Response to Biologics in Severe Asthma with Nasal Polyposis: Insights from the Belgian Severe Asthma Registry

期刊论文
发表日期：

2024年7月15日

查看全文

Femke Demolder,
Eef Vanderhelst,
Sylvia Verbanck,
Florence Schleich,
Renaud Louis,
Guy Brusselle,
Carine Sohy,
Alain Michils,
Rudi Peché,
Charles Pilette,
Shane Hanon

摘要

Background

Nasal polyposis (NP) is a comorbidity of type 2 severe asthma (SA) which could influence response to SA biologics.

Methods

We evaluated (super-) response in SA patients with (NP +) and without NP (NP−) enrolled in the Belgian Severe Asthma Registry (BSAR).

Results

914 patients, of whom 31% NP + , were included. At enrollment, NP + patients had higher annual exacerbation rates, higher number of emergency room visits and more elevated type 2 biomarkers. In the longitudinal subanalysis of 104 patients, both groups had significant and similar asthma responses to asthma biologics, except for a greater increase in FEV₁ in the NP + group. Super-response was achieved in 33 patients (32%), irrespective of NP status or type of biologic.

Conclusion

In conclusion, both NP + and NP − patients had positive treatment responses, with some able to achieve super-response. In SA patients with NP, a greater FEV₁ improvement as compared to SA patients without NP was observed.